NTLA | Page 1 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

9.16

-0.30

(-30.00%)

content_middle

Previous Close:

9.46

52wk Range:

5.90 - 28.18

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

December 3, 2024 - 4:32pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q3
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results

SAGE, MDXG
November 7, 2024 - 8:51am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates

ALNY, IONS, VCEL, AGEN, AXGN, RARE, BLFS, RGNX, CRSP, LENZ, CRBU, VCEL, VERV, EDIT, AGEN, IONS, QURE, BEAM, SAGE, MDXG, ALNY, BPMC, AXGN, RARE
February 20, 2024 - 11:49am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q3
RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes

MDXG, GBIO, AXGN, VCEL, BLFS, QURE, EDIT, VERV, MDXG, VYGR, MESO, RGNX, BEAM, VERV, FATE, NTLA, CRSP, IONS, SAGE, RARE, BPMC, ALNY
August 18, 2023 - 4:09pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings
RegMed Investors (RMi) Research Note: Q2/23 net losses earnings, cash positions and runway outcomes

QURE
July 31, 2023 - 7:19am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q2
RegMed Investors (RMi) Research Note: Q2/2023 earnings reporting date announcements

MDXG, BPMC, VCEL, ALNY, EDIT, NTLA, BEAM, VERV, PRME, CRSP
June 12, 2023 - 11:16am | Out and About, Research Notes, Out and About
RegMed Investors (RMi) Research Note: Intellia Therapeutics (NTLA +$2.30 or +5.32% TO $45.54) pops on news of its CRISPR-based gene-editing drug almost completely eliminated attacks in a rare swelling disease

NTLA
May 27, 2023 - 12:37pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q1
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes

SGMO, SAGE, MDXG, AXGN
April 10, 2023 - 4:40pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

SAGE, RARE, CRSP, EDIT, VCEL, NTLA, QURE, MESO, BEAM, VYGR, KDNY, FIXX, CRBU, AGEN, AXGN, VSTM, BLUE, ADVM, BCLI
December 1, 2022 - 6:56am | Out and About, Research Notes, Out and About, Financings
RegMed investors (RMi) Research Note: Intellia Therapeutics (NTLA) prices offering of 6.25 million shares priced at $45.80

Intellia Therapeutics (NTLA)
August 16, 2022 - 11:38am | Out and About, Research Notes, Out and About
RegMed Investors’ (RMI) Earnings: dates of releases and more results

RARE, ALNY, SAGE, AXGN, VCEL, MDXG, EDIT, FATE, NTLA, AGEN, IONS
May 3, 2022 - 10:45am | Out and About, Research Notes, Out and About
RegMed Investors: The week that will define the cell and gene therapy sector’s share pricing month
March 4, 2022 - 5:10pm | Out and About, Research Notes, Out and About
UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies

CRSP, NTLA, EDIT
February 8, 2022 - 8:07am
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?

BSTG, Biostage (BSTG), IBB, XBI, VVIX, ALNY, EDIT, NTLA, IONS, CRSP, BCLI, SAGE,
September 23, 2021 - 7:10pm | Out and About, Research Notes, Out and About, Earnings Q2
Q2/21 Earnings - (LPS - loss-per-share) Results
July 20, 2021 - 7:47am
RegMed Investors’ (RMi) pre-open: recognition for the oversold or as good as it can get?
July 3, 2021 - 12:45pm | Out and About, Research Notes, Out and About
Intellia Therapeutics (NTLA) closes 4.758 M shares offering priced at $145.00 per share
December 2, 2020 - 8:32am | Out and About, Research Notes, Out and About, Financings
Intellia Therapeutics (NTLA) prices 4.79 million share offering at $36.50

Intellia Therapeutics (NTLA)
June 6, 2020 - 3:22pm | Out and About, Research Notes, Out and About, Financings
Intellia Therapeutics (NTLA) closes $115 million offering

NTLA
May 30, 2020 - 9:44am | Out and About, Research Notes, Out and About, Earnings Q1
RegMed/Cell and Gene Therapy Earnings Scorecard - Q1/20 - to date
April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
Regenerative Medicine Earnings Scorecard - Q4 & FY19

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.